Metabolism Pathways of Major Therapeutics for Treating Monkeypox Mono- and Co-infection with Human Immunodeficient Virus or SARS-CoV-2

• Published in: Current drug metabolism Vol. 24; no. 4; p. 240
• Main Authors: Yan, Daisy, Yan, Bingfang
• Format: Journal Article
• Language: English
• Published: Netherlands 01.01.2023
• Subjects: Coinfection - drug therapy; COVID-19; HIV Infections - complications; HIV Infections - drug therapy; Humans; Mpox (monkeypox); SARS-CoV-2; therapeutic interventions; SARS-CoV-2; HIV; Monkeypox; coinfection; monoinfection
• ISSN: 1875-5453
• DOI: 10.2174/1389200224666230607124102

Monkeypox is a zoonotic viral disease and remains endemic in tropical regions of Central and West Africa. Since May of 2022, cases of monkeypox have soared and spread worldwide. Confirmed cases have shown no travel history to the endemic regions as seen in the past. The World Health Organization declared monkeypox a global public health emergency in July 2022, and the United States government followed suit one month later. The current outbreak, in contrast to traditional epidemics, has high coinfection rates, particularly with HIV (human immunodeficiency virus), and to a lesser extent with SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), the pathogen of COVID-19. No drugs have been approved specifically for monkeypox. However, there are therapeutic agents authorized to treat monkeypox under the Investigational New Drug protocol, including brincidofovir, cidofovir, and tecovirimat. In contrast to limited options for monkeypox treatment, there are available drugs specifically for HIV or SARS-CoV-2 infection. Interestingly, these HIV and COVID-19 medicines share metabolism pathways with those authorized to treat monkeypox, particularly of hydrolysis, phosphorylation, and active membrane transport. This review discusses how these pathways shared by these medicines should be considered to gain therapeutic synergy and maximize safety for treating monkeypox coinfections.